Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Construction will begin this year with the new capacity anticipated by 2025
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
One thousand times more soluble than L-cystine at neutral pH
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
India’s efforts are aimed at boosting health at the last mile
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Subscribe To Our Newsletter & Stay Updated
